Company* |
University/ |
Type Of |
Product Area | Details (Date) |
| | ||||
Affibody AB* |
National Cancer Institute |
Cooperative Research and Development Agreement |
Deal to develop in vivo imaging agents for detecting cancer |
The company will design and develop engineered Affibody molecules specific for HER2; terms were not disclosed (11/8) |
Affymetrix |
CureSearch Children's Oncology Group |
Collaboration |
To discover and validate gene expression signatures for a number of childhood cancers |
They will use Affymetrix's Gene- Chip microarray technology and COG's databank of tumor samples in the effort (10/25) |
Affymetrix |
Chinese Rice Functional Genomic Research Consortium |
Agreement |
CapitalBio will provide Affymetrix GeneChip Rice Genome Array services to the consortium |
CapitalBio is an Affymetrix service provider in China; terms of the deal were not disclosed (10/10) |
Affymetrix |
Jeffrey Modell Foundation and the National Human Genome Research Institute |
Collaboration |
To develop newborn screening tests |
The tests will be for severe combined immunodeficiency and other primary immunodeficiency disorders; the foundation will fund the work (10/5) |
Alnylam |
Stanford University |
License agreement |
The companies got co- exclusive rights to technologies in the area of hepatitis C virus |
The technology relates to the inhibition of the liver-specific microRNA miR-122; terms were not disclosed (9/13) |
Altachem |
Research Centre for Bioactive Materials (Korea) |
Agreement |
They will work together to plan the most appropriate projects for Altachem |
The goal is to establish projects designed to underpin Altachem's discovery programs in cancer (9/8) |
Amaxa GmbH* |
American Type Culture Collection |
Agreement |
ATCC will supply cell lines to Amaxa |
The cell lines will be used to develop and optimize protocols using Amaxa's Nucleofector technology (9/27) |
Ariana |
Institut Pasteur (France) |
Agreements |
Series of deals involving Ariana's new virtual screening platform |
The institute gets an equity stake in Ariana, becomes a customer for Ariana's technology and provides use of its BioTop incubator; specific terms were not disclosed (11/2) |
Avexa Ltd. |
Commonwealth Scientific and Industrial Research Organisation (Australia) |
Collaboration |
Deal to discover drugs for treating viral diseases |
Avexa will screen CSIRO libraries and would develop any resulting compounds (11/9) |
Avidex Ltd.* |
King's College London |
License agreement |
Avidex got exclusive rights to develop products recognizing an antigen associated with Type I diabetes |
Avidex intends to develop soluble monoclonal T-cell receptors targeting KCL's antigen on the islet cells in the pancreas (10/10) |
BioVeris Corp. |
The Rockefeller University |
License agreement |
BioVeris got exclusive rights to technologies related to a Group A Streptococcal disease vaccine candidate |
BioVeris paid a $150,000 license fee and may make additional payments for license maintenance and patent costs, as well as making milestone and royalty payments (9/6) |
CellCentric |
University College London |
Collaboration |
Deal to explore epigenetic- elated cancer cell targets |
CellCentric will work with the university's Wolfson Institute of Biomedical Research in the sponsored research program (11/1) |
CellCentric |
Cancer Research Technology Ltd. (UK) |
Collaboration |
To develop monoclonal antibodies against CellCentric's epigenetic- related cancer target |
They will share the costs and rewards of the effort, which may be followed by co-development of other targets identified by CellCentric (9/26) |
Ceragenix |
Centers for Disease Control and Prevention |
Cooperative Research and Development Agreement |
Letter of intent calls for evaluation of company's cationic steroid antimicrobial coating |
Focus is prevention of bacterial biofilm growth on medical devices; Brigham Young University also is a party to the CRADA (10/25) |
Chemokine |
Wayne State University |
Agreement |
University researchers will conduct preclinical experiments on a Chemokine cancer drug |
The studies will evaluate the ability of CTCE-9908 to inhibit the CXCR4 receptor found on prostate cancer cells (11/16) |
Ciphergen |
University College London |
Research and license agreement |
To further validate and characterize ovarian cancer biomarkers and discover new ones |
Ciphergen will have exclusive rights to license discoveries made during the collaboration (10/6) |
Covalys |
Ecole Polytechnique Fédérale de Lausanne (Switzerland) |
Agreement |
Covalys will exclusively commercialize the school's ACP-tag technology |
Terms on the deal involving protein tag technology were not disclosed (11/7) |
Cryptome |
University of Virginia |
Collaboration expansion |
To further discover compounds that treat vascular leak |
Cryptome gets the first option to license CR104 and other technology developed at the university (9/19) |
Cyberkinetics |
Brown University |
Collaboration |
Brown researchers get access to clinical research data provided by Cyberkinetics |
The company gets options to license inventions derived from the research, which is in the area of neurology (9/8) |
Cygenics Ltd. |
Johns Hopkins University |
Collaboration |
Deal to combine technologies in a preclinical program for acute myeloid leukemia |
The effort will use Cygenics' stem cell expansion platform with Hopkins' stem cell purging technology (11/15) |
Dendritic |
Nanotechnology Characterization Laboratory |
Collaboration |
The NCL will characterize DNT's dendrimers as macromolecular dendrimer-based MRI contrast agents |
The agents will be used for cardiovascular diagnostics; the NCL was established by the National Cancer Institute (10/10) |
Dharmacon Inc. |
Various institutions |
Global initiative |
To advance research using a genome-wide siRNA library |
Dharmacon and 10 research institutions formed the Genome- Wide RNAi Global Initiative (10/6) |
DiscoveRx |
National Institutes of Health |
Collaboration |
DiscoveRx is providing access to its PathHunter technology for small- molecule screening |
Molecules will be screened against targets of interest in the NIH's Molecular Libraries Roadmap initiative (11/3) |
EntreMed Inc. |
National Cancer Institute |
Cooperative Research and Development Agreement |
To evaluate the role of HIF-1-alpha inhibition in the treatment of cancer |
The three-year deal centers on EntreMed's 2ME2 and analogues; terms of the deal were not disclosed (9/15) |
Genentech Inc. |
Accelerate Brain Cancer Cure |
Collaboration |
To explore Genentech's Avastin for treating patients with glioblastoma multiforme |
ABC2 will share expenses in an imaging study and then would provide resources for a Genentech- sponsored trial (10/19) |
Genome |
Centre Léon Bérard and Centre Jean Perrin (both in France) |
Collaboration |
High-throughput sequencing program for the mutational analysis of 300 gene candidates in human cancers |
Results of the research will be made available to researchers; the Mutacancer program is being supported by France's National Cancer Institute (10/28) |
Genzyme Corp. |
University of California at Los Angeles |
License agreement |
Genzyme got exclusive diagnostic rights to gene mutations believed to be associated with resistance to Gleevec |
Genzyme intends to develop a test to detect many BCR-ABL mutations and monitor resist- ance in chronic myeloid leukemia patients (10/6) |
Hemispherx |
National Institute of Infectious Diseases (Japan) |
Research agreement |
The institute will evaluate Hemispherx's Ampligen |
It will assess the product as an adjuvant to its nasal flu vaccine; terms were not disclosed (10/3) |
|
Cancer Research UK |
Services agreement |
Illumina will conduct genotyping studies focused on colorectal cancer |
Illumina's Sentrix Arrays and Infinium Assay will be used in the multimillion-dollar deal (11/8) |
Illumina Inc. |
Children's Hospital Oakland Research Institute |
Agreement |
Illumina will provide reagents and instrumentation for a study by the institute |
The institute is studying the impact of single nucleotide polymorphisms on responses to statins under an NIH- funded program (10/20) |
Illumina Inc. |
Wellcome Trust (UK) |
Collaboration |
To study the impact of those SNPs that cause amino acid changes, on a range of disease samples |
They will design a custom Sentrix BeadChip for the effort; Illumina intends to turn the custom SNP product into a standard micro- array offering (9/28) |
Illumina Inc. |
Max Planck Institute of Psychiatry (Germany) |
Supply agreement |
Illumnia will supply technologies for a large- scale genotyping study |
The institute intends to generate information on genetic variants associated with depression and anxiety (9/20) |
Illumina Inc. |
National Cancer Institute |
Purchase agreement |
The NCI is purchasing an Illumina BeadLab, a production-scale genetic analysis laboratory |
The lab will be used in research into the genetics of breast and prostate cancers, supporting the Cancer Genetic Markers of Susceptibility initiative (9/1) |
Invitrogen |
National Center for Drug Screening (China) |
Collaboration |
Deal focused on the high- throughput screening of compound libraries against nuclear receptors |
The center will use Invitrogen technologies in the effort; terms of the deal were not disclosed (10/31) |
Invitrogen |
Georgia Tech Research Corp. |
License agreement |
Invitrogen got exclusive rights to metal nano-cluster technology |
The small, bright fluorescent particles may be useful in in vivo and in vitro applications (10/6) |
Invitrogen |
Fred Hutchinson Cancer Research Center |
Collaboration |
To develop diagnostics and screening tools for cancer |
Invitrogen has rights to license resulting technologies; terms were not disclosed (9/13) |
iQur Ltd.* |
University of Southampton |
License agreement |
iQur got rights to technology used for treating liver fibrosis |
Terms of the deal were not disclosed (11/8) |
Knopp |
University of Pittsburgh |
License agreement |
Knopp got rights to commercialize a panel of protein biomarkers |
The biomarkers will be used as a diagnostic test for amyotrophic lateral sclerosis (9/7) |
Kreatech BV* |
Institute of Systems Biology (the Netherlands) |
Agreement |
The ISB will use the Universal Linkage System from Kreatech |
The agreement is expected to help Kreatech position the label- ing technology in new application areas (9/21) |
Locus |
Cornell Research Foundation |
License agreement |
Locus licensed a second crystal structure of the fusion protein gp41 |
Locus intends to use the structure to design small-molecule inhibitors of HIV (11/15) |
Lorus |
Ohio State University |
Collaboration |
Deal to study Lorus' GTI-2040 and cytarabine on acute myeloid leukemia cell lines |
Lorus will work with the OSU Comprehensive Cancer Center in the research collaboration (9/7) |
MedImmune |
National Institute of Allergy and Infectious Diseases |
Collaboration |
To produce and test versions of MedImmune's influenza vaccine against potential pandemic strains |
MedImmune also has offered licenses for its reverse genetics technology to U.S. and international authorities and manufacturers developing pandemic influenza vaccines (9/28) |
MedImmune |
Georgetown University |
Collaboration |
To develop monoclonal antibodies targeting anaplastic lymphoma kinase, a member of the insulin receptor family |
Georgetown gets an up-front payment and potential milestones and royalties; MedImmune gets exclusive worldwide rights to the preclinical program (9/26) |
Medivation |
University of California at Los Angeles |
Acquisition |
Medivation acquired the MDVN 300 series of small-molecule compounds |
The compounds target hormone- refractory prostate cancer; terms of the deal were not disclosed (9/19) |
MerLion |
National Cancer Institute |
Cooperative Research and Development Agreement |
To discover and develop small-molecule inhibitors of the hypoxic signaling pathway for treating cancers |
MerLion will perform initial screening of candidate molecules; each party may then further investigate and develop those candidates (10/18) |
MerLion |
Cancer Research Technology Ltd. (UK) |
Collaboration |
Screening program to identify anticancer drugs derived from natural product chemistry |
Resulting technology will be jointly owned (9/20) |
Morphotek |
John Wayne Cancer Institute |
Collaboration |
Deal to discover and develop antibodies to a cancer-associated protein |
Morphotek will apply its Human Morphodoma technology to the protein discovered at JWCI (11/14) |
M-phasys GmbH* |
Fraunhofer Institute (Germany) |
Collaboration |
Deal to discover monoclonal antibodies to GPCR cancer targets |
They will take resulting products through early preclinical testing, then offer them for licensing (11/14) |
MultiCell |
Thomas Jefferson University |
Collaboration |
Deal to evaluate the company's immortalized human hepatocytes |
The focus is their use as model systems to identify new drugs to treat hepatitis C viral infection (10/20) |
Novelos |
Shriners Hospitals for Children |
Collaboration |
Deal to confirm findings in the therapy of acute radiation injury obtained in Russian experiments |
They also plan to more precisely identify the cellular and molecular actions of Novelo's NOV-002 (11/8) |
Novelos |
Medical University of South Carolina |
Collaboration |
To research the mechanisms of Novelos' NOV-002 and NOV-205 products |
Results will help in the design and execution of clinical trials in cancer and hepatitis C, respectively (9/13) |
Perlegen |
Wellcome Trust entities (UK) |
Collaboration |
To conduct whole- genome association studies to search for genes associated with 10 complex diseases |
Perlegen will genotype 15,000 individuals and produce more than 10 billion individual genotypesusing Affymetrix technology; terms were not disclosed (10/5) |
Phylogica Ltd. |
University of Western Australia |
Research collaboration |
UWA will screen Phylogica's library in an effort focused on phosphatases |
One project targets leukemia proteins and a second targets stroke; they will jointly own resulting technology (10/18) |
Phylogica Ltd. |
Massachusetts General Hospital and Johns Hopkins University |
License agreement |
Phylogica gained access to genetic screening technology |
The technology augments the company's drug discovery capabilities; terms were not disclosed (10/18) |
Prima Biomed |
Walter Reed Army Institute of Research |
Cooperative Research and Development Agreement |
Deal to include the DCtag vaccine adjuvant technology in the development of a malaria vaccine |
The deal was signed with Prima subsidiary Panvax Ltd. and the Austin Research Institute; Prima has rights to resulting technology (10/18) |
Reata |
National Cancer Institute |
Cooperative Research and Development Agreement |
Deal for the development of RTA 401 (CDDO), a synthetic triterpenoid |
Agent is a designed to induce programmed cell death in cancer cells by activating redox-sensitive signaling pathways (10/12) |
Saneron CCEL |
University of Minnesota |
License agreement |
Saneron acquired rights to a cord blood cell line from the university |
The university is entitled to research funding and milestone payments; the technology will be used to develop cellular therapies for neurological and cardiac disorders (9/7) |
Santhera |
National Institute of Neurological Disorders and Stroke |
Collaboration |
To evaluate Santhera's SNT-MC17 (idebenone) in patients with Friedreich's ataxia |
The NIH will run a Phase II trial in 48 patients(11/3) |
Sequenom |
University of Oxford (UK) |
License agreement |
Sequenom acquired rights to non- invasive prenatal diagnostic technology |
Isis Innovation Ltd., the technology transfer company of the university, is entitled to up-front fees, milestone payments and royalties on any sales (10/20) |
SIGA |
Saint Louis University |
Agreement |
Deal for the continued development of SIGA's smallpox candidate, SIGA-246 |
SIGA will get $1M to support pre-clinical development; the deal is funded through the National Institutes of Health (9/20) |
Starpharma |
Biomolecular Research Institute Ltd. (Australia) |
Amended agreement |
Starpharma acquired outright ownership of technology that was shared when it was spun out of BRI in 1996 |
Starpharma also acquired the 25% royalty that would be due to BRI; the technology forms the basis for its VivaGel microbicide product; BRI got 7.1M Starpharma shares (10/11) |
Stem Cell |
University of Nice (France) |
License agreement |
Stem Cell got rights to human multipotent adipose-derived stem cells and technologies |
Stem Cells will use the technology to develop cell therapies for degenerative diseases; the university is entitled to up-front fees and milestone and royalty payments (11/15) |
Unigene |
Yale University |
Agreements |
Unigene acquired exclusive rights to jointly owned inventions |
The technology involves procedures for treating and preventing fractures more effectively; Unigene is sponsoring research at Yale (9/19) |
U.S. BioDefense |
National Institutes of Health |
Agreement |
Deal focused on USBD's universal viral inactivation method |
The company said it is evaluating the technology with the NIH; details were not disclosed (11/15) |
Vical Inc. |
National Institute of Allergy and Infectious Diseases |
Cooperative Research and Development Agreement |
To develop electroporation- enhanced delivery of DNA vaccines against HIV |
Vical has an option to get exclusive rights to technology developed under the CRADA (9/12) |
Vion |
University of Innsbruck (Austria) |
License agreement |
Vion licensed a group of heterocyclic hydrazone compounds for cancer applications |
Vion will make an initial payment of $37,500 and could make milestone and royalty payments (9/26) |
Viragen Inc. (AMEX:VRA) |
Roslin Institute (UK) |
Renewed agreement |
They are working on avian transgenic technology as a biomanufacturing platform |
They now are evaluating two candidates that already are on the market; terms were not disclosed (11/1) |
| | ||||
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadaian Venture Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.